(for veterinary information only)
BRAND NAME: ANIPRYL, ELDEPRYL, CARBEX
Monoamine oxidases are enzymes we have in two areas: the brain (monoamine oxidase inhibitor -B) and in the liver/GI tract (monoamine oxidase inhibitor -A). In the brain, these enzymes break down used neurotransmitters (chemicals that enable nerves to communicate). One of these neurotransmitters is called dopamine. Type B monoamine oxidases are responsible for getting rid of dopamine when it is no longer needed. Sometimes, however, it is beneficial to have dopamine stick around a bit. Selegiline hydrochloride in the body is converted into three products: two stimulants and a type B monoamine oxidase inhibitor (an MAO-B inhibitor). These three products all produce the effects of selegiline hydrochloride.
There are two approved indications for in dogs: the treatment of pituitary-dependent Cushing’s disease, an excess in corticosteroid hormone production stemming from a pituitary tumor, and the treatment of senile mental deterioration (canine cognitive dysfunction). The use of in dogs with Cushing's disease has met with limited success despite its FDA approval for this use. Since trilostane and lysodren are virtually the only medications used for Cushing's disease, you may wish to skip the Cognitive Dysfunction section. S is not approved for use in cats but studies have shown it to be helpful in feline cognitive dysfunction as well.
Cushing’s disease is the insidious debilitating hormone imbalance that results when the adrenal glands overproduce cortisone. Most cases (85%) occur as the result of a tumor in the pituitary gland that produces a stimulatory hormone called ACTH. This hormone leads both adrenal glands to enlarge and overproduce cortisone, which in turn leads to symptoms associated with Cushing’s disease.
Treatment has traditionally centered on suppressing adrenal gland production and release of cortisone but this approach has been fraught with potential for side effects. S has allowed for a new approach by suppressing the pituitary gland directly.
Monoamine oxidases are enzymes we have in two areas: the brain (monoamine oxidase inhibitor -B) and in the liver/GI tract (monoamine oxidase inhibitor-A). In the brain, these enzymes break down used neurotransmitters (chemicals that enable nerves to communicate). One of these neurotransmitters is called dopamine and one of its functions is the regulation, specifically the inhibition, of ACTH.
By using a monoamine oxidase-B inhibitor, dopamine is not broken down; instead, it persists and provides extra inhibition of ACTH. S further acts on the enzymes that produce dopamine so that more dopamine is produced.
S is a monoamine oxidase inhibitor specific to the brain’s monoamine oxidases; those of the liver/GI tract are not affected. This effect on ACTH inhibition allows for the treatment of pituitary dependent Cushing’s disease in dogs as well as the treatment of Parkinson’s syndrome in humans.
Because of the unique way that works as treatment for Cushing’s disease, the usual tests needed/used to monitor response to therapy will not be relevant. Assessment of effect is solely by the owner’s perception of improvement in symptoms. There is presently no way to determine prior to treatment if a dog has a pars intermedia tumor which is likely to respond to but it is generally clear if a dog is responding or not within 3 months of therapy (see below).
An additional effect of stems from an interaction with brain enzymes that destroy free radicals. By helping to rid the brain of destructive free radicals, has proven useful in treating Parkinson’s disease in humans as well as canine cognitive dysfunction (senility) in dogs. S was approved in the dog first for the treatment of Cushing’s disease but has since been approved for the treatment of canine cognitive dysfunction.
Pet owners have long been frustrated by age-related behavior problems involving loss of house-training, apparent memory loss or disorientation, sleep disturbances (either waking at the wrong time or sleeping unusually deeply) and loss of interest in social activities with the family. Such behavior changes are often written off as being normal aging. One study at the University of California Davis School of Veterinary Medicine demonstrates how common these observations are: out of 69 dogs participating, 32% of 11 year old dogs were affected by this syndrome and that 100% of dogs 16 years of age older were affected.
Still, the high frequency with which the syndrome is seen in older dogs does not make it normal. Other studies have shown that dogs affected by this syndrome show deposition of a protein called amyloid in their brains in patterns similar to the amyloid plaques found in the brains of humans with Alzheimer’s disease.
Cognitive dysfunction is associated with depletion of dopamine, the neurotransmitter mentioned above. As described above, also helps prolong dopamine activity, which may account for part of its efficacy in treating cognitive dysfunction. Further, dopamine breakdown results in harmful biochemicals known as free radicals. The use of selegiline hydrochloride also helps reduce amounts of free radicals in the brain. The stimulating metabolites are also helpful in improving activity of senior patients, though, these same metabolites can also be responsible for adverse reactions as described below.
HOW THIS MEDICATION IS USED
S is given once a day for two months. If no response is seen in this time, the dose is doubled for an additional month. If still no response is seen, another form of treatment should be pursued. Of the 69 dogs with cognitive dysfunction mentioned above, approximately 76% showed improvement on after one month of therapy. Some dogs improve in the first few days or weeks, some dogs do not show improvement until the second month. Often dogs would continue to improve during the first three months.
Selegiline hydrochloride is given once daily, with or without food. If a dose is accidentally skipped, the next dose should be given as scheduled. Do not double up on medication doses.
S has been used in conjunction with alprazolam and propranolol for phobias.
There is a 5% incidence of unacceptable side effects with treatment. These side effects include: vomiting, diarrhea, appetite loss, itchy skin, tremors, drooling, listlessness, disorientation, diminished hearing, or restlessness.
When three times the recommended dose was used in dogs, salivation, weight loss, panting, dehydration, pacing, and poor pupil response to light were observed. Obviously these signs should not be observed with normal use of the medication.
It should be noted that after oral administration, selegiline hydrochloride is processed by the liver to produce amphetamine and methamphetamine, both of which are stimulants. Humans that take selegiline hydrochloride have reported assorted behavioral side effects so it is important to watch for undesirable changes that might be resulting from the medication.
INTERACTIONS WITH OTHER DRUGS
Probably the most serious adverse reaction/drug interaction that could occur with selegiline hydrochloride is "serotonin syndrome." Serotonin syndrome is a potential side effect that can occur if brain levels of serotonin get too high. Elevated heart rate, tremors/shivering, dilated pupils, difficulty breathing, elevated body temperature, or high blood pressure can all be signs of serotonin syndrome. Animals with serotonin syndrome sometimes demonstrate general hyperactivity as a sign that something is wrong. Death can result if blood pressure rises too high. Because of this syndrome, medications that elevate serotonin levels should not be combined. The following interactions are avoided to prevent the possibility of serotonin syndrome.
For More Information on Canine Cognitive Dysfunction, click here.
Page last updated: 4/12/2020